Table 5.
High Grade PCa (Gleason sum ≥7) |
Low Grade PCa (Gleason sum 2–6) |
|||
---|---|---|---|---|
Number at risk (events) |
Multivariate hazard ratio (95% CI) * |
Number at risk (events) |
Multivariate hazard ratio (95% CI) * |
|
Total body BMD (g/cm2) | ||||
First Quartile | 1111 (41) | 1.00 | 1100 (30) | 1.00 |
Second Quartile | 1100 (27) | 0.64 (0.40–1.04) | 1113 (40) | 1.23 (0.76–1.98) |
Third Quartile | 1115 (39) | 0.93 (0.60–1.44) | 1103 (27) | 0.85 (0.50–1.43) |
Fourth Quartile | 1117 (21) | 0.43 (0.25–0.74) † | 1121 (25) | 0.79 (0.46–1.36) |
P-value for trend | 0.01 | 0.21 | ||
Total hip BMD (g/cm2) | ||||
First Quartile | 1125 (40) | 1.00 | 1108 (23) | 1.00 |
Second Quartile | 1108 (22) | 0.54 (0.32–0.92) ‡ | 1125 (39) | 1.67 (0.99–2.82) |
Third Quartile | 1119 (37) | 0.86 (0.54–1.38) | 1111 (29) | 1.28 (0.73–2.24) |
Fourth Quartile | 1118 (30) | 0.63 (0.38–1.06) | 1119 (31) | 1.41 (0.80–2.50) |
P-value for trend | 0.21 | 0.46 | ||
Spine BMD (g/cm2) | ||||
First Quartile | 1121 (29) | 1.00 | 1118 (26) | 1.00 |
Second Quartile | 1115 (40) | 1.40 (0.87–2.26) | 1108 (33) | 1.26 (0.75–2.13) |
Third Quartile | 1108 (30) | 1.03 (0.62–1.72) | 1116 (38) | 1.59 (0.96–2.62) |
Fourth Quartile | 1123 (29) | 0.91 (0.54–1.54) | 1118 (24) | 1.07 (0.61–1.87) |
P-value for trend | 0.43 | 0.51 |
Adjusted for age, race, BMI, family history of prostate cancer, physical activity, statin use, and calcium intake
p <0.01
p <0.05